Illumenex Corp.
This article was originally published in Start Up
Executive Summary
Phototherapy; Restenosis. Illumenex is using light-activated psoralen to prevent the neointimal hyperplasia that occurs after balloon angioplasty with or without stent implantation and causes blood vessel restenosis.
You may also be interested in...
Restenosis: Multi-Billion-Dollar Market Tempts Many
A variety of approaches are being used to combat the problem of restenosis following angioplasty. In addition to separate drug and device efforts, several companies are working on drug-device collaborations to prevent restenosis.
polyGenomics Inc.
PolyGenomics was spun-out of Yale University to develop a genetic amplification technology in the search for genes implicated in psychiatric illnesses.
Oxagen Ltd.
Oxagen's goal is to use large familial clinical groups and sample banks to identify disease genes through agreements with three groups of academic clinical investigators, located throughout Europe.